<DOC>
	<DOC>NCT00467506</DOC>
	<brief_summary>Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)</brief_summary>
	<brief_title>Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Neuroendocrine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Bispecific</mesh_term>
	<criteria>18 75 years Karnofsky ≥ 70% Histological diagnosis of medullary thyroid carcinoma Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years Normal liver and renal functions Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3 No immunization Consent form signed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Recurrence of medullary thyroid carcinoma: abnormal calcitonin level and biomarkers doubling time lower than 5 years after initial surgery</keyword>
</DOC>